ReviewCurrent treatment options in oncology2015
Review of Recommended Treatment of Uterine Carcinosarcoma.
Review in Current treatment options in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Impact of Lymphadenectomy on Outcomes of Early-Stage Ovarian Cancer: A Systematic Review and Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).Journal of gynecologic oncology · 2018Trial
- Risk factors and treatment strategies for female reproductive system carcinosarcoma with metastasis.Translational cancer research · 2025Article
- Odontogenic carcinosarcoma: a comprehensive review of clinical and therapeutic insights.Frontiers in oral health · 2025Review
- Uterine carcinosarcoma: Unraveling the role of epithelial-to-mesenchymal transition in progression and therapeutic potential.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Review
- Article
- Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique.PloS one · 2023Observational
- The prognostic significance of the heterologous component in uterine carcinosarcomas.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Uterine fibroid-like tumors: spectrum of MR imaging findings and their differential diagnosis.Abdominal radiology (New York) · 2022Review
- Carcinosarcoma of the Cervix: A Case Report.JNMA; journal of the Nepal Medical Association · 2021Article
- Carcinosarcomas of the Uterus: Prognostic Factors and Impact of Adjuvant Treatment.Cancer management and research · 2021Article
- Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma.Disease markers · 2021Article
- Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases.Molecular and clinical oncology · 2020Article
- Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2020Review
- Current Status of Magnetic Resonance Imaging in Patients with Malignant Uterine Neoplasms: A Review.Korean journal of radiology · 2019Review
- Diagnostic Value ofNuclear medicine and molecular imaging · 2018Article
- Uterine carcinosarcoma (malignant mixed Müllerian tumor): case report in a goat and literature review.Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2018Article
- Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study.Oncology · 2018Article
- Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma.Journal of gynecologic oncology · 2017Article
- Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study.Journal of gynecologic oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgery is the primary treatment for uterine carcinosarcoma (UCS). Lymphadenectomy should be performed for staging purposes in tumors apparently confined to the uterus. Most studies found that lymphadenectomy is of therapeutic value. The therapeutic value of cytoreduction to no residual macroscopic disease in advanced UCS is based mostly on small retrospective uncontrolled studies. Postoperative adjuvant therapy should be considered for all stages of UCS. Adjuvant pelvic radiotherapy may reduce locoregional recurrences. However, this does not translate into improved overall survival since most recurrences are distant outside the irradiated field, and the survival rates remain poor, the 5-year overall survival being about 50%. Several adjuvant platin-based combination chemotherapy schedules such as cisplatin/ifosfamide, ifosfamide/paclitaxel, and paclitaxel/carboplatin have been found to be an effective mode of adjuvant treatment. Multimodal therapy (i.e., adjuvant chemotherapy plus radiotherapy) has also been shown to be effective. Most studies dealing with adjuvant treatment are retrospective and prospective randomized controlled trials (i.e., phase III studies) comparing that between the various adjuvant chemotherapy schedules and between them and multimodal treatment are lacking. Quality of life with the various treatment modalities needs also to be assessed. An effective targeted therapy has so far not been found. In spite of the multiple studies with regard to the treatment of UCS published during the last 15 years, the optimal management of UCS is still not established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.